Study of IMC-EB10 in Participant With Leukemia

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine if IMC-EB10 is safe for participants with leukemia, and also to determine the best dose of IMC-EB10 to give to participants.

Clinical Trial Description

The purpose of this study is to define the maximum tolerated dose (MTD) and the pharmacokinetic (PK) profile of the anti-FMS-like tyrosine kinase 3 (FLT3) monoclonal antibody IMC-EB10, administered weekly in participant with acute lymphoblastic leukemia (AML) who have failed to achieve complete remission to a standard induction regimen, relapsed after response to previous antileukemia therapy, or are not eligible for potentially curative or approved salvage options. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00887926
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Terminated
Phase	Phase 1
Start date	June 2009
Completion date	August 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00001637` - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults	Phase 2
Terminated	`NCT00543972` - Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia	Phase 1
Completed	`NCT00521664` - A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups	Phase 3
Completed	`NCT05363488` - Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
Completed	`NCT01380756` - Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia	Phase 1
Recruiting	`NCT05031897` - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant	Phase 2
Terminated	`NCT00126893` - Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia	Phase 1
Completed	`NCT03613727` - Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients	Phase 2
Active, not recruiting	`NCT04714372` - FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia	Phase 1
Completed	`NCT02763475` - NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents	Phase 2
Terminated	`NCT01643603` - Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies	Phase 1
Completed	`NCT00497991` - Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia	Phase 1
Not yet recruiting	`NCT05787951` - Frequency and Risk Factors of Acute Myeloid Leukemia
Completed	`NCT04628338` - IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation	Early Phase 1
Completed	`NCT02719821` - Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation	N/A
Active, not recruiting	`NCT00111345` - Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents	Phase 2/Phase 3
Completed	`NCT00114764` - Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)	Phase 2
Recruiting	`NCT05871008` - Integrated Actionable Aging Assessment for Cancer Patients Pilot	N/A
Recruiting	`NCT03638206` - Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies	Phase 1/Phase 2
Recruiting	`NCT05035706` - Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors	Early Phase 1